by nikki mann | Jul 10, 2023 | News
We were excited to welcome ∼500 delegates at West Road Concert Hall for our annual Symposium on July 5th, with a further 300+ UK and international delegates opting to view the talks online. A small selection of photographs can already be found on our website, with...
by nikki mann | May 19, 2023 | News
We are delighted that several of our affiliated companies were recognised at the 2023 Cambridge Independent Science & Technology Awards last night. Among the list of awardees was Cardiatec Biosciences, an AI drug target discovery company co-founded by Milner Head...
by nikki mann | Apr 3, 2023 | News
We are delighted to welcome Dr Cathy Tralau-Stewart as the new Executive Director at the Milner Therapeutics Institute. Cathy will work alongside Director Tony Kouzarides and the Milner team to lead and deliver our vision to transform pioneering science into...
by nikki mann | Mar 17, 2023 | News
We are delighted to welcome Dr Erica Bello as the new Head of Target Discovery at the Milner Therapeutics Institute. Erica brings to the team broad experience in CRISPR screening and advanced disease models, both from her work at the Wellcome Sanger Institute and more...
by nikki mann | Feb 21, 2023 | News
The AI Club for Biomedicine, launched earlier this month, is a new initiative created to bring together the biomedical AI and machine learning community in Cambridge. This collaboration between the Milner and CRUK Cambridge Institute will be held on the first Thursday...
by nikki mann | Jan 18, 2023 | News
We are delighted to announce a new collaboration with the NC3Rs this month, which has been established to help NC3Rs-funded researchers translate their in vitro models of human disease into industry-relevant genetic assays. The collaboration involves a funding...
by nikki mann | Dec 7, 2022 | News
Congratulations to Milner affiliated company STORM Therapeutics, who have announced the start of phase I clinical trials with their first-in-class compound against the RNA modifying enzyme, METTL3. STORM Therapeutics is a clinical stage biotechnology company creating...
by nikki mann | Nov 29, 2022 | News
This month we are excited to announce that MSD has joined the Milner Therapeutics Consortium as our 12th pharma partner. This coincides with the company’s investment in a new Discovery Centre in London, located in the heart of the Knowledge Quarter. MSD scientists in...
by nikki mann | Nov 23, 2022 | News
A long-term priority for the Milner is to share our experience of working with industry with other academic institutes, with the goal of fostering wider cross-sector collaboration. Colleagues from affiliated academic institutes have participated in our annual...
by nikki mann | Nov 16, 2022 | News
We are delighted that Dr Manav Pathania and team, who are based at the Milner Therapeutics Institute, have been awarded ~£1 million from Cancer Research UK, to investigate paediatric high-grade gliomas. These rare brain tumours account for less than 20% of brain...
